FOLLOW US

A Philadelphia jury has delivered a sharp rebuke to Johnson & Johnson, handing down a $250,000 verdict Friday in a lawsuit brought by the family of a woman who alleged the company’s once-iconic talcum powder contributed to her fatal ovarian cancer.

The decision came after a three-week trial and three-and-a-half days of deliberations in the courtroom of Philadelphia County Court of Common Pleas Judge Sean Kennedy. Closing arguments wrapped Feb. 10, with the plaintiff’s attorney urging jurors to “send a message” to the health care giant.

First Plaintiffs’ Victory in Years

The verdict — $50,000 in compensatory damages and $200,000 in punitive damages — marks the first plaintiffs’ win in Philadelphia’s sprawling talc mass tort, which encompasses roughly 175 cases. It follows a 2021 defense verdict in the city’s first talc trial favoring Johnson & Johnson.

The nearly five-year pause between trials stemmed from a court-ordered stay while litigation addressed bankruptcy proceedings tied to Johnson & Johnson’s spun-off talc unit — a procedural detour that froze momentum in the local docket.

Compared with towering awards handed down elsewhere, Friday’s verdict is modest. In December, juries in Baltimore and Los Angeles delivered judgments of $1.5 billion and $40 million, respectively, to talc plaintiffs. In October, a California court issued a staggering $966 million judgment in another talc case. Against that backdrop, Philadelphia’s award may look small — but symbolically, it carries weight.

Plaintiffs: “The Evidence Could Not Be More Clear”

At closing arguments, Leigh O’Dell of Beasley Allen Law Firm, representing the estate of Gayle Emerson, accused Johnson & Johnson of concealing the presence of asbestos in its baby powder for decades.

“Johnson & Johnson hid the presence of asbestos in Johnson’s baby powder from the FDA, the regulators, and people like Ms. Emerson since the 1960s,” O’Dell told jurors. “The evidence could not be more clear.”

When pressing for punitive damages, O’Dell pointed jurors to the company’s net worth — $72.27 billion, according to a slide presented at trial — arguing that any award should be large enough to resonate.

“Whatever the amount is, it should be enough in light of this net worth to send a message,” she said.

Defense: Alternative Risk Factors at Play

Defense attorneys countered that the plaintiff’s team selectively presented evidence and failed to prove that Emerson’s ovarian cancer was caused by Johnson & Johnson’s baby powder.

Kirkland & Ellis LLP attorney Shaila Diwan told jurors that Emerson had engaged in regular douching, a practice she argued is associated with an increased risk of ovarian cancer. Diwan also cited obesity and age as contributing factors.

“They want to put their talc blinders on,” Diwan said during trial, suggesting the plaintiff’s case overlooked other medical realities.

Diwan further argued that hereditary factors made it likely Emerson would have developed cancer regardless of product use.

“What the evidence has shown is that it wasn’t Johnson’s baby powder,” she told jurors.

The Woman at the Center

Gayle Emerson, a Philadelphia native and tax preparer, died in 2019 after filing suit. Her estate pursued the claims following her death, becoming part of the city’s consolidated talc litigation.

Emerson and her estate were represented by Leigh P. O’Dell, David P. Dearing, Ted G. Meadows and Ryan Beattie of Beasley Allen Law Firm, along with Richard M. Golomb and Kevin W. Fay of Golomb Legal.

Johnson & Johnson was represented by Shaila Diwan of Kirkland & Ellis LLP, Michael A. Brown of Nelson Mullins Riley & Scarborough LLP, and Chanda Miller, Thomas E. Hanson Jr., and Rebecca Trela of Barnes & Thornburg LLP.

As the courtroom emptied and the jury’s message echoed through Philadelphia’s long-running talc litigation, the $250,000 award signaled a renewed pulse in a docket that had sat dormant for years — a reminder that even after delays and detours, accountability claims can return to center stage.